Protective effects of cyclooxygenase-2 gene inactivation against peripheral nerve dysfunction and intraepidermal nerve fiber loss in experimental diabetes

Diabetes

Volumn 56, Issue 12, 2007, Pages 2997-3005

  Kellogg, Aaron P ^a   Wiggin, Tim D ^a   Larkin, Dennis D ^a   Hayes, John M ^a   Stevens, Martin J ^b   Pop Busui, Rodica ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; GLUCOSE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETIC NEUROPATHY; ELECTROPHYSIOLOGY; ENZYME ACTIVATION; ENZYME INACTIVATION; EPIDERMIS; EXPERIMENTAL DIABETES MELLITUS; EXPERIMENTAL STUDY; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; INFLAMMATION; MALE; MOTOR NERVE CONDUCTION; MOUSE; NERVE FIBER; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SENSORY NERVE CONDUCTION; SPINAL GANGLION; TREATMENT DURATION; UPREGULATION; WILD TYPE;

ANIMALS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; MICE; MOTOR NEURONS; NERVE FIBERS; NEURAL CONDUCTION; PERIPHERAL NERVES;

EID: 36849058141     PISSN: 00121797     EISSN: 00121797     Source Type: Journal    
DOI: 10.2337/db07-0740     Document Type: Article

References (50)

1. Vileikyte L, Leventhal H, Gonzalez JS, Peyrot M, Rubin RR, Ulbrecht JS, Garrow A, Waterman C, Cavanagh PR, Boulton AJ: Diabetic peripheral neuropathy and depressive symptoms: the association revisited. Diabetes Care 28:2378-2383, 2005
2. Gordois A, Scuffham P, Shearer A, Oglesby A, Tobian JA: The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care 26:1790-1795, 2003
3. American Diabetes Association: Economic consequences of diabetes mellitus in the U.S. in 1997. Diabetes Care 21:296-309, 1998
4. The Diabetes Control and Complications Trial Research Group: The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 122:561-568, 1995
5. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993 [see comments]
6. Ho EC, Lam KS, Chen YS, Yip JC, Arvindakshan M, Yamagishi S, Yagihashi S, Oates PJ, Ellery CA, Chung SS, Chung SK: Aldose reductase-deficient mice are protected from delayed motor nerve conduction velocity, increased c-Jun NH2-terminal kinase activation, depletion of reduced glutathione, increased superoxide accumulation, and DNA damage. Diabetes 55:1946-1953, 2006
7. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 414:813-820, 2001
8. Yagihashi S, Yamagishi SI, Wada Ri R, Baba M, Hohman TC, Yabe-Nishimura C, Kokai Y: Neuropathy in diabetic mice overexpressing human aldose reductase and effects of aldose reductase inhibitor. Brain 124:2448-2458, 2001
9. Song Z, Fu DT, Chan YS, Leung S, Chung SS, Chung SK: Transgenic mice overexpressing aldose reductase in Schwann cells show more severe nerve conduction velocity deficit and oxidative stress under hyperglycemic stress. Mol Cell Neurosci 23:638-647, 2003
10. King GL, Ishii H, Koya D: Diabetic vascular dysfunctions: a model of excessive activation of protein kinase C. Kidney Int Suppl 60:S77-S85, 1997
11. Pop-Busui R, Marinescu V, Van Huysen C, Li F, Sullivan K, Greene DA, Larkin D, Stevens MJ: Dissection of metabolic, vascular, and nerve conduction interrelationships in experimental diabetic neuropathy by cyclooxygenase inhibition and acetyl-L-carnitine administration. Diabetes 51:2619-2628, 2002
12. Herschman HR, Reddy ST, Xie W: Function and regulation of prostaglandin synthase-2. Adv Exp Med Biol 407:61-66, 1997
13. Wu KK: Inducible cyclooxygenase and nitric oxide synthase. Adv Pharmacol 33:179-207, 1995
14. Cosentino F, Eto M, De Paolis P, van der Loo B, Bachschmid M, Ullrich V, Kouroedov A, Delli Gatti C, Joch H, Volpe M, Luscher TF: High glucose causes upregulation of cyclooxygenase-2 and alters prostanoid profile in human endothelial cells: role of protein kinase C and reactive oxygen species. Circulation 107:1017-1023, 2003
15. Feng L, Xia Y, Garcia GE, Hwang D, Wilson CB: Involvement of reactive oxygen intermediates in cyclooxygenase-2 expression induced by interleukin-1, tumor necrosis factor-alpha, and lipopolysaccharide. J Clin Invest 95:1669-1675, 1995
16. Kellogg A, Pop-Busui R: Peripheral nerve dysfunction in experimental diabetes is mediated by cyclooxygenase-2 and oxidative stress. Antioxid Redox Signal 7:1521-1529, 2005
17. Stevens MJ, Obrosova I, Cao X, Van Huysen C, Greene DA: Effects of DL-α-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy. Diabetes 49:1006-1015, 2000
18. Cain DM, Wacnik PW, Turner M, Wendelschafer-Crabb G, Kennedy WR, Wilcox GL, Simone DA: Functional interactions between tumor and peripheral nerve: changes in excitability and morphology of primary afferent fibers in a murine model of cancer pain. J Neurosci 21:9367-9376, 2001
19. Polydefkis M, Hauer P, Griffin JW, McArthur JC: Skin biopsy as a tool to assess distal small fiber innervation in diabetic neuropathy. Diabetes Technol Ther 3:23-28, 2001
20. Rousseeuw P: Silhouettes: a graphical aid to the interpretation and validation of cluster analysis. J Comput Appl Math 20:53-65, 1987
21. Welsh JB, Zarrinkar PP, Sapinoso LM, Kern SG, Behling CA, Monk BJ, Lockhart DJ, Burger RA, Hampton GM: Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci U S A 98:1176-1181, 2001
22. Cipollone F, Iezzi A, Fazia M, Zucchelli M, Pini B, Cuccurullo C, De Cesare D, De Blasis G, Muraro R, Bei R, Chiarelli F, Schmidt AM, Cuccurullo F, Mezzetti A: The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation 108:1070-1077, 2003
23. Adderley SR, Fitzgerald DJ: Oxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2-mediated induction of cyclooxygenase-2. J Biol Chem 274:5038 -5046, 1999
24. Kiritoshi S, Nishikawa T, Sonoda K, Kukidome D, Senokuchi T, Matsuo T, Matsumura T, Tokunaga H, Brownlee M, Araki E: Reactive oxygen species from mitochondria induce cyclooxygenase-2 gene expression in human mesangial cells: potential role in diabetic nephropathy. Diabetes 52:2570-2577, 2003
25. Uchida K, Kumagai T: 4-hydroxy-2-nonenal as a COX-2 inducer. Mol Aspects Med 24:213-218, 2003
26. Bagi Z, Erdei N, Toth A, Li W, Hintze TH, Koller A, Kaley G: Type 2 diabetic mice have increased arteriolar tone and blood pressure: enhanced release of COX-2-derived constrictor prostaglandins. Arterioscler Thromb Vasc Biol 25:1610 -1616, 2005
27. Guo Z, Su W, Allen S, Pang H, Daugherty A, Smart E, Gong MC: COX-2 up-regulation and vascular smooth muscle contractile hyperreactivity in spontaneous diabetic db/db mice. Cardiovasc Res 67:723-735, 2005
28. Baber SR, Champion HC, Bivalacqua TJ, Hyman AL, Kadowitz PJ: Role of cyclooxygenase-2 in the generation of vasoactive prostanoids in the rat pulmonary and systemic vascular beds. Circulation 108:896-901, 2003
29. Belton OA, Duffy A, Toomey S, Fitzgerald DJ: Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis. Circulation 108:3017-3023, 2003
30. Quilley J, Chen YJ: Role of COX-2 in the enhanced vasoconstrictor effect of arachidonic acid in the diabetic rat kidney. Hypertension 42:837-843, 2003
31. Liang X, Wang Q, Hand T, Wu L, Breyer RM, Montine TJ, Andreasson K: Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer's disease. J Neurosci 25:10180-10187, 2005
32. Consilvio C, Vincent AM, Feldman EL: Neuroinflammation, COX-2, and ALS: a dual role? Exp Neurol 187:1-10, 2004
33. Kaufmann WE, Worley PF, Pegg J, Bremer M, Isakson P: COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc Natl Acad Sci U S A 93:2317-2321, 1996
34. Kulmacz RJ, Wang LH: Comparison of hydroperoxide initiator requirements for the cyclooxygenase activities of prostaglandin H synthase-1 and -2. J Biol Chem 270:24019-24023, 1995
35. Yabuki A, Tahara T, Taniguchi K, Matsumoto M, Suzuki S: Neuronal nitric oxide synthase and cyclooxygenase-2 in diabetic nephropathy of type 2 diabetic OLETF rats. Exp Anim 55:17-25, 2006
36. Komers R, Zdychova J, Cahova M, Kazdova L, Lindsley JN, Anderson S: Renal cyclooxygenase-2 in obese Zucker (fatty) rats. Kidney Int 67:2151-2158, 2005
37. Yagihashi S, Kamijo M, Ido Y, Mirrlees DJ: Effects of long-term aldose reductase inhibition on development of experimental diabetic neuropathy: ultrastructural and morphometric studies of sural nerve in streptozocin-induced diabetic rats. Diabetes 39:690-696, 1990
38. Kennedy WR, Wendelschafer-Crabb G, Johnson T: Quantitation of epidermal nerves in diabetic neuropathy. Neurology 47:1042-1048, 1996
39. Hanson P, Schumacker P, Debugne T, Clerin M: Evaluation of somatic and autonomic small fibers neuropathy in diabetes. Am J Phys Med Rehabil 71:44-47, 1992
40. Lacomis D: Small-fiber neuropathy. Muscle Nerve 26:173-188, 2002
41. McArthur JC, Stocks EA, Hauer P, Cornblath DR, Griffin JW: Epidermal nerve fiber density: normative reference range and diagnostic efficiency. Arch Neurol 55:1513-1520, 1998
42. Herrmann DN, Griffin JW, Hauer P, Cornblath DR, McArthur JC: Epidermal nerve fiber density and sural nerve morphometry in peripheral neuropathies. Neurology 53:1634-1640, 1999
43. Periquet MI, Novak V, Collins MP, Nagaraja HN, Erdem S, Nash SM, Freimer ML, Sahenk Z, Kissel JT, Mendell JR: Painful sensory neuropathy: prospective evaluation using skin biopsy. Neurology 53:1641-1647, 1999
44. Mukherjee D, Nissen SE, Topol EJ: Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286:954-959, 2001
45. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR Study Group. N Engl J Med 343:1520-1528, 2000
46. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352:1092-1102, 2005
47. Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, Grosser T, Lawson JA, FitzGerald GA: Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 296:539-541, 2002
48. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352:1071-1080, 2005
49. Levesque LE, Brophy JM, Zhang B: The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med 142:481-489, 2005
50. Sowers JR, White WB, Pitt B, Whelton A, Simon LS, Winer N, Kivitz A, van Ingen H, Brabant T, Fort JG: The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med 165:161-168, 2005